RESEARCH PAPER
Treatment compliance and therapy satisfaction in HIV-infected patients
More details
Hide details
Submission date: 2018-01-25
Final revision date: 2018-04-15
Acceptance date: 2018-04-19
Publication date: 2018-09-25
HIV & AIDS Review 2018;17(3):164-168
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Adherence to the prescribed therapy is the most important factor influencing the treatment outcome. The aim of study was to assess human immunodeficiency virus (HIV) patients’ compliance and satisfaction with recommended antiretroviral and concomitant therapies.
Material and methods:
A survey was conducted among HIV-infected patients. Therapeutic regimens for HIV and co-morbidities were described by the number of daily doses and total daily number of tablets. Patients’ satisfaction was assessed on a six-point scale, and a Visual Analogue Scale (VAS) was used to assess the compliance with a recommended therapy.
Results:
A total of 120 patients (M = 87, F = 33) aged 18-72 (46 ± 15) years with HIV treated for 1-288 (109 ± 77) months filled in the questionnaire. Patients received 1-9 tablets in 1-3 doses a day as part of the antiretroviral therapy – 36% of subjects received only one tablet a day, and 74% received treatment in one daily dose. Eighty-nine percent of subjects were ‘very satisfied’ and ‘satisfied’ with the received anti-HIV treatment. Therapeutic compliance was the best for patients receiving only one tablet per day as single-tablet regimens (STR). Eighty patients also received 1-21 tablets in 1 – > 3 daily doses of co-morbidities therapy. Fifty-four percent of patients received non-HIV therapy in one single dose. Eighty-one percent of subjects were ‘very satisfied’ and ‘satisfied’ with treatment for other-than-HIV diseases.
Conclusions:
In the population under study, patients’ compliance and satisfaction with both HIV and non-HIV concomitant disease therapies were high. The compliance with recommended HIV therapy was the best for patients receiving only one tablet per day, and the satisfaction with antiretroviral treatment was greater in patients receiving ≤ 2 tablets per day.
REFERENCES (22)
1.
Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2000; 31: 123-127.
2.
Schaker KL. The importance of Treatment Adherence in HIV. Am J Manag Care 2013; 19 (12 Suppl): 231-237.
3.
Aguiar C, Antela A, Compston J, et al. Going beyond undetectable: a review of the unmet long-term health needs of people living with HIV. HIV Therapy 2015; 1: 1-12.
4.
Rasmussen LD, May MT, Kronborg G, et al. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. Lancet HIV 2015; 2: e288.
5.
Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing populationinfected with HIV: a modelling study. Lancet Infect Dis 2015; 15: 810-818.
6.
Warrine AH, Greer A, Burkholder GA, Overton ET. HIV-Related Metabolic Comorbidities in the Current ART Era. Infect Dis Clin N Am 2014; 28: 457-476.
7.
Kapiamba G, Masango T, Mphuthi D. Antiretroviral adherence and virological outcomes in HIV-positive patients in Ugu district, KwaZulu-Natal province. Afr J AIDS Res 2016; 15: 195-201.
8.
Hasabi IS, Shivashankarappa AB, Kachapur C, Kaulgud RS. A Study of Compliance to Antiretroviral Therapy among HIV Infected Patients at a Tertiary Care Hospital in North Karnataka. J Clin Diagn Res 2016;10: 27-31.
9.
Wójcik K, Piekarska A, Jabłonowska E. Adherence to Antiviral Therapy in HIV ir HBV Infected patients. Przegl Epidemiol 2016; 70: 27-32.
10.
Molassiotis A, Lopez-Nahas V, Chung WY, Lam SW. A pilot study of the effects of a behavioural intervention on treatment adherence in HIV-infected patients. AIDS Care 2003; 15: 125-135.
11.
Dagli-Hernandez C, Lucchetta RC, de Nadai TR, et al. Self-perception of knowledge and adherence reflecting the effectiveness of antiretroviral therapy. Patient Prefer Adherence 2016; 10: 1787-1793.
12.
Lima IC, Galvão MT, Alexandre Hde O, et al. Information and communication technologies for adherence to antiretroviral treatment in adults with HIV/AIDS. Int J Med Inform 2016; 92: 54-61.
13.
Kim HM, Lagakos SW. Assessing drug compliance using longitudinal marker data, with application to AIDS. Stat Med 1994; 13: 2141-2153.
14.
Wilson IB, Lee Y, Michaud J, et al. Validation of a New Three-Item Self-Report Measure for Medication Adherence. AIDS Behav 2016; 20: 2700-2708.
15.
Parczewski M, Siwak E, Leszczyszyn-Pynka M, et al. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristic. J Int AIDS Soc 2017; 20: 21847.
16.
Bezabhe WM, Chalmers L, Bereznicki LR, Person GM. Adherence to Antiretroviral Therapy and Virologic Failure. A Meta-Analysis. Medicine (Baltimore) 2016; 95: e3361.
17.
Huan Z, Fuzhi W, Lu L, et al. Comparison of Adherence to Antiretroviral Therapy in a High-Risk Population in China: A Systematic Review and Meta-Analysis. PLoS One 2016; 11: 20146659.
18.
Sebaaly JC, Kelley D. Single-Tablet Regimens for the Treatment of HIV-1 Infection. Ann Pharmacother 2017; 51: 332-344.
19.
Langness J, Cook PF, Gil J, et al. Comparison of adherence rates for antiretroviral, blood pressure, or mental health medications for hiv-positive patients at an academic medical center outpatient pharmacy. J Manag Care Spec Pharm 2014; 20: 809-814.
20.
Jimenez Galan R, Montes Escalante IM, Morillo Verdugo R. Influence of pharmacotherapy complexity on compliance with the therapeutic objectives for HIV+ patients on ART concomitant with therapy for dyslipidemia. INCOFAR Project Farm Hosp 2016; 40: 90-101.
21.
Lemos LA, Fiuza ML, Reis RK, et al. Adherence to antiretrovirals in people coinfected with human immunodeficiency virus and tuberculosis. Rev Lat Am Enfermagen 2016; 24: e2691.
22.
Batchelder AW, Gonzalez JS, Berg KM. Differential medication nonadherence and illness beliefs in co-morbid HIV and type 2 diabetes. J Behav Med 2014; 37: 266-275.